IGC Pharma

IGC

Market cap $28M

New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma's Leadership in Alzheimer's Innovation POTOMAC, MD / ACCESS Newswire / December 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced the publication of "Caring for a Loved One with Alzheimer's Disease: First Hand Experiences," a comprehensive caregiver-focused book sponsored by IGC Pharma and authored by several of the world's leading experts in neuropsychology and dementia care. The book written by renowned clinical neuropsychologists Dr. Juan Carlos Arango-Lasprilla and Dr. Sandra Báez, alongside co-authors Dr. Valeria Villamizar, and Dr. Natalia Valech presents science-based education, practical strategies, and real-life narratives from families impacted by Alzheimer's disease.

POTOMAC, MD / ACCESS Newswire / November 25, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced advances in MINT-AD, the Multimodal Interpretable Transformer for Alzheimer's. Leveraging data from the Health and Retirement Study (HRS) International Family of Studies, IGC Pharma aims to identify unknown socioeconomic risk factors and their interactions influencing aging and cognitive decline.

Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership POTOMAC, MARYLAND / ACCESS Newswire / November 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced financial results for the quarter ended September 30, 2025 (Second Quarter of Fiscal Year 2026) and provided a compelling update on its accelerated clinical and strategic progress. Q2 FY 2026 Strategic and Operational Highlights Strategic Financial Discipline: Executed a strategic divestiture of a non-core manufacturing facility for $2.7 million (fair value, September 29, 2025), booking a non-cash profit of approximately $1.1 million, while eliminating $600 thousand in annual operating expenses.

IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.02 per share a year ago.

POTOMAC, MARYLAND / ACCESS Newswire / November 13, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today announced that the United States Patent and Trademark Office ("USPTO") has granted the company U.S. Patent No. 12,465,589, titled "Methods and Composition for Treating CNS Disorders.

POTOMAC, MARYLAND / ACCESS Newswire / November 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced that the Company will host a conference call and webcast on Monday, November 17, 2025, at 11:00 a.m. Eastern Time to review the Company's operational progress for the second quarter and mid-year period ended September 30, 2025.

POTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced an expansion of its AI-powered in-Silico drug discovery platform. The company is now integrating more methodologies, including retrosynthetic analysis, molecular docking, toxicology and genotoxic assessments, and predictive bioactivity modeling, to accelerate the identification and optimization of therapeutic candidates for Alzheimer's disease (AD) and related disorders.

IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ASM, IGC and RY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 24, 2025.

IGC, SCRYY, RY, UVE and ASM have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 24, 2025.